Affinity DataIC50: 0.200nMAssay Description:Inhibition of GST-fused human FLT3 cytoplasmic domain (amino acids 564 to 993) using Ulight-JAK1 as substrate after 1 hr by TR-FRET assayMore data for this Ligand-Target Pair
Affinity DataIC50: 0.300nMAssay Description:Inhibition of GST-fused human FLT3 cytoplasmic domain (amino acids 564 to 993) using Ulight-JAK1 as substrate after 1 hr by TR-FRET assayMore data for this Ligand-Target Pair
Affinity DataIC50: 0.600nMAssay Description:Inhibition of GST-fused human FLT3 cytoplasmic domain (amino acids 564 to 993) using Ulight-JAK1 as substrate after 1 hr by TR-FRET assayMore data for this Ligand-Target Pair
Affinity DataIC50: 0.600nMAssay Description:Inhibition of GST-fused human FLT3 cytoplasmic domain (amino acids 564 to 993) using Ulight-JAK1 as substrate after 1 hr by TR-FRET assayMore data for this Ligand-Target Pair
Affinity DataIC50: 1nMAssay Description:Inhibition of GST-fused human FLT3 cytoplasmic domain (amino acids 564 to 993) using Ulight-JAK1 as substrate after 1 hr by TR-FRET assayMore data for this Ligand-Target Pair
Affinity DataIC50: 1nMAssay Description:Inhibition of GST-fused human FLT3 cytoplasmic domain (amino acids 564 to 993) using Ulight-JAK1 as substrate after 1 hr by TR-FRET assayMore data for this Ligand-Target Pair
Affinity DataIC50: 1nMAssay Description:Inhibition of CDK4/cyclin D1 (unknown origin) using Rb as substrate after 60 mins by scintillation counting analysis in presence of [r-33P]ATPMore data for this Ligand-Target Pair
Affinity DataIC50: 1nMAssay Description:Inhibition of CDK4/cyclin D1 (unknown origin) using Rb as substrate after 60 mins by scintillation counting analysis in presence of [r-33P]ATPMore data for this Ligand-Target Pair
Affinity DataIC50: 1nMAssay Description:Inhibition of CDK4/cyclin D1 (unknown origin) using Rb as substrate after 60 mins by scintillation counting analysis in presence of [r-33P]ATPMore data for this Ligand-Target Pair
Affinity DataIC50: 2nMpH: 7.5Assay Description:The total assay volume was about 100 μL in the following configuration: 2-μL compound in DMSO, 88 μL buffer with protein and probe and...More data for this Ligand-Target Pair
Affinity DataIC50: 2nMAssay Description:Inhibition of GST-fused human FLT3 cytoplasmic domain (amino acids 564 to 993) using Ulight-JAK1 as substrate after 1 hr by TR-FRET assayMore data for this Ligand-Target Pair
Affinity DataIC50: 2nMAssay Description:Inhibition of GST-fused human FLT3 cytoplasmic domain (amino acids 564 to 993) using Ulight-JAK1 as substrate after 1 hr by TR-FRET assayMore data for this Ligand-Target Pair
Affinity DataIC50: 2nMAssay Description:Inhibition of GST-fused human FLT3 cytoplasmic domain (amino acids 564 to 993) using Ulight-JAK1 as substrate after 1 hr by TR-FRET assayMore data for this Ligand-Target Pair
Affinity DataIC50: 2nMAssay Description:Inhibition of GST-fused human FLT3 cytoplasmic domain (amino acids 564 to 993) using Ulight-JAK1 as substrate after 1 hr by TR-FRET assayMore data for this Ligand-Target Pair
Affinity DataIC50: 2nMAssay Description:Inhibition of CDK4/cyclin D1 (unknown origin) using Rb as substrate after 60 mins by scintillation counting analysis in presence of [r-33P]ATPMore data for this Ligand-Target Pair
Affinity DataIC50: 2nMAssay Description:Inhibition of CDK4/cyclin D1 (unknown origin) using Rb as substrate after 60 mins by scintillation counting analysis in presence of [r-33P]ATPMore data for this Ligand-Target Pair
Affinity DataIC50: 2nMAssay Description:Inhibition of CDK4/cyclin D1 (unknown origin) using Rb as substrate after 60 mins by scintillation counting analysis in presence of [r-33P]ATPMore data for this Ligand-Target Pair
Affinity DataIC50: 2nMAssay Description:Inhibition of CDK4/cyclin D1 (unknown origin) using Rb as substrate after 60 mins by scintillation counting analysis in presence of [r-33P]ATPMore data for this Ligand-Target Pair
Affinity DataIC50: 2nMAssay Description:Inhibition of CDK4/cyclin D1 (unknown origin) using Rb as substrate after 60 mins by scintillation counting analysis in presence of [r-33P]ATPMore data for this Ligand-Target Pair
Affinity DataIC50: 2nMAssay Description:Inhibition of CDK4/cyclin D1 (unknown origin) using Rb as substrate after 60 mins by scintillation counting analysis in presence of [r-33P]ATPMore data for this Ligand-Target Pair
Affinity DataIC50: 3nMAssay Description:Inhibition of CDK4/cyclin D1 (unknown origin) using Rb as substrate after 60 mins by scintillation counting analysis in presence of [r-33P]ATPMore data for this Ligand-Target Pair
Affinity DataIC50: 3nMAssay Description:Inhibition of GST-fused human FLT3 cytoplasmic domain (amino acids 564 to 993) using Ulight-JAK1 as substrate after 1 hr by TR-FRET assayMore data for this Ligand-Target Pair
Affinity DataIC50: 3nMAssay Description:Inhibition of GST-fused human FLT3 cytoplasmic domain (amino acids 564 to 993) using Ulight-JAK1 as substrate after 1 hr by TR-FRET assayMore data for this Ligand-Target Pair
Affinity DataIC50: 3nMAssay Description:Inhibition of CDK4/cyclin D1 (unknown origin) using Rb as substrate after 60 mins by scintillation counting analysis in presence of [r-33P]ATPMore data for this Ligand-Target Pair
Affinity DataIC50: 3nMAssay Description:Inhibition of CDK4/cyclin D1 (unknown origin) using Rb as substrate after 60 mins by scintillation counting analysis in presence of [r-33P]ATPMore data for this Ligand-Target Pair
Affinity DataIC50: 3nMAssay Description:Inhibition of CDK4/cyclin D1 (unknown origin) using Rb as substrate after 60 mins by scintillation counting analysis in presence of [r-33P]ATPMore data for this Ligand-Target Pair
Affinity DataIC50: 3nMAssay Description:Inhibition of CDK4/cyclin D1 (unknown origin) using Rb as substrate after 60 mins by scintillation counting analysis in presence of [r-33P]ATPMore data for this Ligand-Target Pair
Affinity DataIC50: 3nMAssay Description:Inhibition of CDK4/cyclin D1 (unknown origin) using Rb as substrate after 60 mins by scintillation counting analysis in presence of [r-33P]ATPMore data for this Ligand-Target Pair
Affinity DataIC50: 3nMAssay Description:Inhibition of CDK4/cyclin D1 (unknown origin) using Rb as substrate after 60 mins by scintillation counting analysis in presence of [r-33P]ATPMore data for this Ligand-Target Pair
Affinity DataIC50: 3nMAssay Description:Inhibition of CDK4/cyclin D1 (unknown origin) using Rb as substrate after 60 mins by scintillation counting analysis in presence of [r-33P]ATPMore data for this Ligand-Target Pair
Affinity DataIC50: 3nMAssay Description:Inhibition of CDK4/cyclin D1 (unknown origin) using Rb as substrate after 60 mins by scintillation counting analysis in presence of [r-33P]ATPMore data for this Ligand-Target Pair
Affinity DataIC50: 4nMAssay Description:Inhibition of CDK4/cyclin D1 (unknown origin) using Rb as substrate after 60 mins by scintillation counting analysis in presence of [r-33P]ATPMore data for this Ligand-Target Pair
Affinity DataIC50: 4nMAssay Description:Inhibition of CDK4/cyclin D1 (unknown origin) using Rb as substrate after 60 mins by scintillation counting analysis in presence of [r-33P]ATPMore data for this Ligand-Target Pair
Affinity DataIC50: 4nMAssay Description:Inhibition of GST-fused human FLT3 cytoplasmic domain (amino acids 564 to 993) using Ulight-JAK1 as substrate after 1 hr by TR-FRET assayMore data for this Ligand-Target Pair
Affinity DataIC50: 4nMAssay Description:Inhibition of GST-fused human FLT3 cytoplasmic domain (amino acids 564 to 993) using Ulight-JAK1 as substrate after 1 hr by TR-FRET assayMore data for this Ligand-Target Pair
Affinity DataIC50: 5nMAssay Description:Inhibition of CDK4/cyclin D1 (unknown origin) using Rb as substrate after 60 mins by scintillation counting analysis in presence of [r-33P]ATPMore data for this Ligand-Target Pair
Affinity DataIC50: 5nMAssay Description:Inhibition of CDK4/cyclin D1 (unknown origin) using Rb as substrate after 60 mins by scintillation counting analysis in presence of [r-33P]ATPMore data for this Ligand-Target Pair
Affinity DataIC50: 5nMAssay Description:Inhibition of GST-fused human FLT3 cytoplasmic domain (amino acids 564 to 993) using Ulight-JAK1 as substrate after 1 hr by TR-FRET assayMore data for this Ligand-Target Pair
Affinity DataIC50: 5nMAssay Description:Inhibition of GST-fused human FLT3 cytoplasmic domain (amino acids 564 to 993) using Ulight-JAK1 as substrate after 1 hr by TR-FRET assayMore data for this Ligand-Target Pair
Affinity DataIC50: 5nMAssay Description:Inhibition of GST-fused human FLT3 cytoplasmic domain (amino acids 564 to 993) using Ulight-JAK1 as substrate after 1 hr by TR-FRET assayMore data for this Ligand-Target Pair
Affinity DataIC50: <5nMpH: 7.5Assay Description:The total assay volume was about 100 μL in the following configuration: 2-μL compound in DMSO, 88 μL buffer with protein and probe and...More data for this Ligand-Target Pair
Affinity DataIC50: <5nMpH: 7.5Assay Description:The total assay volume was about 100 μL in the following configuration: 2-μL compound in DMSO, 88 μL buffer with protein and probe and...More data for this Ligand-Target Pair
Affinity DataIC50: <5nMpH: 7.5Assay Description:The total assay volume was about 100 μL in the following configuration: 2-μL compound in DMSO, 88 μL buffer with protein and probe and...More data for this Ligand-Target Pair
Affinity DataIC50: <5nMpH: 7.5Assay Description:The total assay volume was about 100 μL in the following configuration: 2-μL compound in DMSO, 88 μL buffer with protein and probe and...More data for this Ligand-Target Pair
TargetEndothelial PAS domain-containing protein 1(Homo sapiens (Human))
Peloton Therapeutics
US Patent
Peloton Therapeutics
US Patent
Affinity DataIC50: <5nMAssay Description:HIF-2a: The total assay volume was about 100 uL in the following configuration: 2 uL compound in 100% DMSO, 88 uL buffer with protein and probe and 1...More data for this Ligand-Target Pair
TargetEndothelial PAS domain-containing protein 1(Homo sapiens (Human))
Peloton Therapeutics
US Patent
Peloton Therapeutics
US Patent
Affinity DataIC50: <5nMAssay Description:HIF-2a: The total assay volume was about 100 uL in the following configuration: 2 uL compound in 100% DMSO, 88 uL buffer with protein and probe and 1...More data for this Ligand-Target Pair
TargetEndothelial PAS domain-containing protein 1(Homo sapiens (Human))
Peloton Therapeutics
US Patent
Peloton Therapeutics
US Patent
Affinity DataIC50: <5nMAssay Description:HIF-2a: The total assay volume was about 100 uL in the following configuration: 2 uL compound in 100% DMSO, 88 uL buffer with protein and probe and 1...More data for this Ligand-Target Pair
TargetEndothelial PAS domain-containing protein 1(Homo sapiens (Human))
Peloton Therapeutics
US Patent
Peloton Therapeutics
US Patent
Affinity DataIC50: <5nMAssay Description:HIF-2a: The total assay volume was about 100 uL in the following configuration: 2 uL compound in 100% DMSO, 88 uL buffer with protein and probe and 1...More data for this Ligand-Target Pair
TargetEndothelial PAS domain-containing protein 1(Homo sapiens (Human))
Peloton Therapeutics
US Patent
Peloton Therapeutics
US Patent
Affinity DataIC50: <5nMAssay Description:HIF-2a: The total assay volume was about 100 uL in the following configuration: 2 uL compound in 100% DMSO, 88 uL buffer with protein and probe and 1...More data for this Ligand-Target Pair
TargetEndothelial PAS domain-containing protein 1(Homo sapiens (Human))
Peloton Therapeutics
US Patent
Peloton Therapeutics
US Patent
Affinity DataIC50: <5nMAssay Description:HIF-2a: The total assay volume was about 100 uL in the following configuration: 2 uL compound in 100% DMSO, 88 uL buffer with protein and probe and 1...More data for this Ligand-Target Pair